Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
The pharmacokinetics of CGP 15 210 G, a new 5-HT uptake inhibitor in poor and extensive metabolisers of debrisoquine, give indirect evidence of an association between its metabolism and polymorphic hydroxylation of the debrisoquine type.
D000328:Adult; D003647:Debrisoquin / Q000378:metabolism*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006900:Hydroxylation; D007546:Isoquinolines / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D010641:Phenotype; D010880:Piperidines / Q000378:metabolism*; D011110:Polymorphism, Genetic; D012701:Serotonin / Q000378:metabolism
D007546:Isoquinolines; D010880:Piperidines; D012701:Serotonin; C046382:ifoxetine; D003647:Debrisoquin